U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06838676) titled 'ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas' on Feb. 19.
Brief Summary: This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Diffuse Intrinsic Pontine Gliomas (DIPG)
Progressive DIPG
Refractory DIPG
Recurrent DIPG
H3K27-altered High Grade Glioma
Intervention:
DRUG: ACT001
PO BID at 875 mg/m2 for 28 days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Nationwide Children's Hospital
Published by HT Digital Content Services with p...